Bluebird’s Latest Gene Therapy Stumble Will Help Vertex Close The Gap
Gene Therapy Launch Delayed Again
Once the darling of biotech investors, Bluebird Bio’s go-it-alone strategy with Zynteglo has not paid off as German launch plans stall.
You may also be interested in...
Vertex is advancing its sodium channel inhibitor VX-548 to mid-stage trials in the second half of the year as a potential treatment for pain after bunionectomy and abdominoplasty procedures.
After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.
The jury is still out on the case of MDS and some remaining questions regarding the AML case may still hinder commercial uptake.